CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 31 enrolled
Drug / intervention
Bevacizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01736449
NCT01736449Phase 4Completed
CompareCT.gov

Role of Sub-Conjunctival Bevacizumab in Post Pterygium Excision Management

Arrowhead Regional Medical Center·interventional·Posted Nov 29, 2012·Updated Nov 29, 2012

In Brief

A Phase 4 clinical trial evaluating Bevacizumab for Pterygium. Completed, enrolled 31 participants across 1 site.

Detailed Summary

A pterygium is a fibrovascular growth originating from the conjunctiva that grows onto the surface of the cornea. Frequently, these pterygia will recur even after surgical resection. Bevacizumab is an inhibitor of angiogenesis, which is needed for recurrent growth. The use of bevacizumab is poorly understood in inhibiting pterygium growth. The objective of this study is to compare the effects of wound healing and recurrence rates in postoperative bevacizumab versus pterygium excision alone.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPterygium
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedNov 29, 2012
Enrollment StartApr 1, 2011
Primary CompletionApr 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 13.6 years ago

Interventions

Bevacizumabdrug